ストックスクリーナーアプリを入手
1.87
3.31%
0.06
前日終値:
$1.81
開ける：
$1.8
24時間の取引高:
669.18K
Relative Volume:
1.16
時価総額：
$67.22M
収益：
$210.70K
当期純損益:
$-21.37M
株価収益率:
-1.70
EPS:
-1.1
ネットキャッシュフロー:
$-21.10M
1週間 パフォーマンス:
-5.08%
1か月 パフォーマンス:
+18.35%
6か月 パフォーマンス:
+3.89%
1年 パフォーマンス:
-32.49%
1日の値動き範囲:
$1.74
$1.895
1週間の範囲:
$1.74
$2.09
52週間の値動き範囲:
$1.41
$2.90
Gain Therapeutics Inc Stock (GANX) Company Profile
GANX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.87 | 65.07M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-06 | 開始されました | ROTH MKM | Buy |
| 2024-08-14 | 再開されました | Oppenheimer | Outperform |
| 2021-04-12 | 開始されました | BTIG Research | Buy |
| 2021-04-12 | 開始されました | Oppenheimer | Outperform |
Gain Therapeutics Inc (GANX) 最新ニュース
Is Gain Therapeutics Inc. stock a defensive play in 2025Market Sentiment Report & Precise Trade Entry Recommendations - Trung tâm Dự báo KTTV quốc gia
Gain Therapeutics’ (GANX) Buy Rating Reiterated at BTIG Research - Defense World
How to build a dashboard for Gain Therapeutics Inc. stockDollar Strength & Free High Accuracy Swing Entry Alerts - newser.com
How to forecast Gain Therapeutics Inc. trends using time series2025 Analyst Calls & AI Driven Stock Reports - newser.com
Is Gain Therapeutics Inc. still worth holding after the dipWeekly Profit Report & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Gain Therapeutics Inc. stock entering bullish territoryEarnings Recap Report & Low Risk Entry Point Tips - newser.com
Gain Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Custom strategy builders for tracking Gain Therapeutics Inc.July 2025 Big Picture & Community Consensus Trade Signals - newser.com
Is Gain Therapeutics Inc a good long term investmentEarnings Miss Alerts & Exceptional Growth Portfolio - earlytimes.in
Gain Therapeutics to Attend the 2025 Maxim Growth Summit - The Manila Times
Oct 22: Gene Mack to Speak — Gain Therapeutics at 2025 Maxim Growth Summit on Neurodegenerative Panel - Stock Titan
What recovery options are there for Gain Therapeutics Inc.Quarterly Growth Report & Weekly High Return Opportunities - newser.com
BTIG Reiterates Gain Therapeutics (GANX) Buy Recommendation - Nasdaq
Intraday pattern recognizer results for Gain Therapeutics Inc.Buy Signal & Community Verified Trade Alerts - newser.com
Institutional scanner results for Gain Therapeutics Inc.July 2025 Chart Watch & Reliable Momentum Entry Alerts - newser.com
Gain Therapeutics, Inc Hosts Key Opinion Leader Event on GT-02287 - TradingView
Gain Therapeutics (NASDAQ:GANX) Given “Buy” Rating at HC Wainwright - Defense World
How risky is Gain Therapeutics Inc. stock nowJuly 2025 Patterns & Entry and Exit Point Strategies - newser.com
Certain Options of Gain Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-OCT-2025. - MarketScreener
Certain Common Stock of Gain Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-OCT-2025. - MarketScreener
Will Gain Therapeutics Inc. stock benefit from sector rotationEarnings Trend Report & Weekly High Return Forecasts - newser.com
HC Wainwright & Co. Reiterates Gain Therapeutics (GANX) Buy Recommendation - Nasdaq
What does recent volatility data suggest for Gain Therapeutics Inc.Earnings Miss & High Return Trade Opportunity Guides - newser.com
Published on: 2025-10-10 04:06:35 - newser.com
Eric Richman Resigns from Gain Therapeutics Board - TipRanks
Allosteric small molecule therapies in PD, with Gene Mack - pharmaphorum
Is Gain Therapeutics Inc. stock cheap at current valuationBreakout Watch & Daily Stock Trend Watchlist - newser.com
Is it time to cut losses on Gain Therapeutics Inc.2025 Momentum Check & Free Expert Verified Stock Movement Alerts - newser.com
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease - The Manila Times
Gain Therapeutics to Host Virtual KOL Event on GT-02287 and Parkinson's Disease Research - Quiver Quantitative
Applying big data sentiment scoring on Gain Therapeutics Inc.Weekly Gains Report & AI Driven Price Forecasts - newser.com
Gain Therapeutics (NASDAQ:GANX) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Gain Therapeutics Supports Reliable Data Management In Labs - Kalkine Media
Gain Therapeutics (NASDAQ:GANX) Given New $7.00 Price Target at Maxim Group - Defense World
Maxim Group Maintains Gain Therapeutics (GANX) Buy Recommendation - Nasdaq
Maxim Group Raises Price Target for Gain Therapeutics (GANX) to - GuruFocus
Gain Therapeutics reports preliminary Phase 1b data for Parkinson’s drug GT-02287 - Investing.com
Stock Traders Buy High Volume of Gain Therapeutics Call Options (NASDAQ:GANX) - MarketBeat
Gain Therapeutics reports positive early data from Parkinson’s trial - Investing.com
Gain Therapeutics reports positive early data from Parkinson’s trial By Investing.com - Investing.com Australia
Gain Therapeutics Reports Positive Interim Data from Phase 1b Study of GT-02287 in Parkinson’s Disease - Quiver Quantitative
Gain Therapeutics' GT-02287 Shows UPDRS Improvement in 9 by Day 90 | GANX Stock News - Stock Titan
What to do if you’re stuck in Gain Therapeutics Inc.Breakout Watch & Daily Stock Trend Watchlist - newser.com
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 61.6% in September - MarketBeat
Detecting price anomalies in Gain Therapeutics Inc. with AITrade Analysis Report & Verified Stock Trade Ideas - newser.com
Gain Therapeutics Inc (GANX) 財務データ
収益
当期純利益
現金流量
EPS
1.84%
0.50%
大文字化:
|
ボリューム (24 時間):